Alpha Teknova Inc Revenue Growth Rates (TKNO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Alpha Teknova Inc   (NASDAQ: TKNO)
 

TKNO's Revenue Growth by Quarter and Year

Alpha Teknova Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TKNO/growth
https://api.csimarket.com/api/v1/companies/TKNO/fundamentals
https://api.csimarket.com/api/v1/companies/TKNO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TKNO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.70
2nd Quarter June 12.19
1st Quarter March 10.78
FY 35.67

TKNOs Annual Revenue
Alpha Teknova Inc 's Revenue in the fiscal year 2025 $ 40.44 millions
Alpha Teknova Inc 's Revenue in the fiscal year 2024 $ 37.23 millions
Alpha Teknova Inc 's Revenue in the fiscal year 2023 $ 36.30 millions
Alpha Teknova Inc 's Revenue in the fiscal year 2022 $ 41.42 millions
Alpha Teknova Inc 's Revenue in the fiscal year 2021 $ 36.89 millions




TKNO Revenue third quarter 2026 Y/Y Growth Comment
Alpha Teknova Inc achieved in the third quarter 2026, above Company average Revenue growth of 21.57% year on year, to $ 12.70 millions.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 4 other companies have achieved higher Revenue growth. While Alpha Teknova Inc ' s Revenue rise of 21.57% ranks overall at the positon no. 2286 in the third quarter 2026.


TKNO Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 21.57 %
2nd Quarter June 22.14 %
1st Quarter March 19.64 %
FY   -

Financial Statements
Alpha Teknova Inc 's third quarter 2026 Revenue $ 12.70 millions TKNO's Income Statement
Alpha Teknova Inc 's third quarter 2025 Revenue $ 10.45 millions Quarterly TKNO's Income Statement


TKNO Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.22 %
2nd Quarter June 13.08 %
1st Quarter March 8.02 %
FY (Year on Year)   -


Back to TKNO Growth rate Comparisons >> Back to TKNO Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #5
Healthcare Sector #332
Overall #2286

Revenue Y/Y Growth Statistics
High Average Low
30.57 % 3.85 % -18.52 %
(Jun 30 2022)   (Sep 30 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #5
Healthcare Sector #332
Overall #2286
Revenue Y/Y Growth Statistics
High Average Low
30.57 % 3.85 % -18.52 %
(Jun 30 2022)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Alpha Teknova Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
48.64 % 4.51 % -32.48 %
(Sep 30 2020)  


TKNO's III. Quarter Q/Q Revenue Comment
Alpha Teknova Inc achieved in the III. Quarter 2026 below company average Revenue growth of 4.22% quarter on quarter, to $ 12.70 millions.

Within In Vitro & In Vivo Diagnostic Substances industry only one company achieved higher sequential Revenue growth. While Alpha Teknova Inc 's Revenue growth quarter on quarter, overall rank is 705.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #117
Overall #705
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #117
Overall #705
Revenue Q/Q Growth Statistics
High Average Low
48.64 % 4.51 % -32.48 %
(Sep 30 2020)  


TKNO's III. Quarter Q/Q Revenue Comment
Alpha Teknova Inc achieved in the III. Quarter 2026 below company average Revenue growth of 4.22% quarter on quarter, to $ 12.70 millions.

Within In Vitro & In Vivo Diagnostic Substances industry only one company achieved higher sequential Revenue growth. While Alpha Teknova Inc 's Revenue growth quarter on quarter, overall rank is 705.


Alpha Teknova Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 43.41
Y / Y Revenue Growth (TTM) 13.6 %
Year on Year Revenue Growth Overall Ranking # 1324
Seqeuential Revenue Change (TTM) 5.34 %
Seq. Revenue Growth (TTM) Overall Ranking # 2286


Cumulative Revenue growth Comment
Alpha Teknova Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 13.6% year on year, to $ 43 millions if the fiscal year would have ended in Jun 30 2026.
Alpha Teknova Inc 's trailing twelve months Revenue growth was higher than company's average 3.85% and higher than 11.28% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 5.34 % from $41.21 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 3.85%.

In the Healthcare sector 228 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1324, from total ranking in previous quarter at 1975.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 229
Overall # 1324

Revenue TTM Y/Y Growth Statistics
High Average Low
30.57 %
 3.85 %
-18.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 332
S&P 500 # 2286
Cumulative Revenue growth Comment
Alpha Teknova Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 13.6% year on year, to $ 43 millions if the fiscal year would have ended in Jun 30 2026.
Alpha Teknova Inc 's trailing twelve months Revenue growth was higher than company's average 3.85% and higher than 11.28% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 5.34 % from $41.21 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 3.85%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 5.34 % increase from $41.21 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 228 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1324, from total ranking in previous quarter at 1975.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 229
Overall # 1324

Revenue TTM Y/Y Growth Statistics
High Average Low
30.57 %
3.85 %
-18.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 332
S&P 500 # 2286




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TKNO's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Biofrontera Inc 29.79%$ 29.794 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions


About Alpha Teknova Inc Revenue Growth Rates (TKNO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alpha Teknova Inc (CIK 1850902).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001850902-26-000017
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alpha Teknova Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.